公司人员任命 - Vera Therapeutics公司于2024年6月7日任命Christy J. Oliger为董事会成员[1] - 公司CEO表示Oliger的经验和建议对公司推进atacicept开发和商业计划有价值[2] 人员履历 - Oliger在生物制药行业有30多年经验 擅长组建高效团队和领导商业产品发布[1] - 目前在多个上市公司董事会任职 包括Karyopharm Therapeutics Replimune Group和LAVA Therapeutics[3] - 曾在Sierra Oncology（2022年被GSK收购）Reata Pharmaceuticals（2023年被Biogen收购）RayzeBio（2024年被Bristol Myers Squibb收购）等公司董事会任职[3] - 2017 - 2020年在Genentech担任高级副总裁 肿瘤业务部门负责人 在多个治疗领域担任高级商业领导角色 也担任过高级研发角色[3] - 拥有加州大学圣巴巴拉分校经济学学士学位[3] 公司业务 - Vera Therapeutics是一家临床后期生物技术公司 专注于开发严重免疫疾病的治疗方法[4] - 公司主要产品候选物atacicept是一种融合蛋白 每周皮下注射一次 可阻断B细胞活化因子和增殖诱导配体 用于治疗IgAN和狼疮性肾炎等自身免疫疾病 公司也在评估atacicept对其他疾病的治疗作用[4] - 公司正在开发MAU868 一种单克隆抗体 用于中和BK病毒感染[4] - 公司保留atacicept和MAU868的全球开发和商业权利[4]

"We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be a valuable resource for the executive team as we advance the development of atacicept for the treatment of IgAN and begin planning for atacicept's potential commercial launch," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. Ms. Oliger currently serves on multiple public company boards, including Karyopharm Therapeutics, Replimune Group, and LAVA T ...

About Vera Each stock option granted on June 4, 2024 has an exercise price per share equal to $39.47 per share, Vera's closing trading price on June 4, 2024. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. Each ...

BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept for the treatment of IgAN. The designation reflects the FDA's determination that, based on an assessment of data from the Phase 2b ORIGI ...

BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept for the treatment of IgAN. The designation reflects the FDA's determination that, based on an assessment of data from the Phase 2b ORIGI ...

文章核心观点 - 公司宣布其IgAN(免疫球蛋白A肾病)治疗药物atacicept在72周数据中显示稳定肾功能,并且能够快速改善血尿[1][2] - 公司认为atacicept可能提供全面的IgAN疾病修饰作用[2] - 公司计划在2024年第四季度发布96周数据,并在2025年上半年公布III期临床试验的主要终点数据[7] 根据目录分别总结 72周数据显示疾病修饰作用 - 72周数据显示atacicept能够稳定肾功能,并且能够快速和持续改善血尿[1][2] - 72周数据被选为最佳排名摘要[3] - 公司认为这些数据支持atacicept可能提供长期全面的IgAN疾病修饰作用[2] 血尿改善结果 - 36周数据的事后分析显示,与安慰剂相比,atacicept组有更多参与者的血尿得到缓解(80%比5%, p<0.001)[4][5] - atacicept组血尿等级快速和持续下降,在4周内就出现血尿等级下降,而安慰剂组血尿等级变化很小[4] - 这些结果进一步支持atacicept作为潜在的IgAN疾病修饰治疗[4] 未来计划 - 计划在2024年第四季度发布96周数据[7] - III期ORIGIN 3试验预计在2024年第三季度完成主要终点入组,2025年上半年公布主要终点数据[7]

BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria. These data were presented at ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2744449 (State or other jurisd ...

Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results BRISBANE, Calif., May 9, 2024 – Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2024. "This quarter, we shared results from our Phase 2b clinical trial th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-40407 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2744449 (State or other jurisdiction ...